Rho kinase inhibitor fasudil suppresses the vasculogenic mimicry of B16 mouse melanoma cells both in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 14, Issue 7, 2015, Pages 1582-1590

  Xia, Yun ^a   Cai, Xian Yi ^a   Fan, Ji Quan ^a   Zhang, Li Ling ^a   Ren, Jing Hua ^a   Chen, Jing ^a   Li, Zhen Yu ^a   Zhang, Rui Guang ^a   Zhu, Fang ^a   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FASUDIL; MESSENGER RNA; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; PROTEIN KINASE INHIBITOR; ROCK1 PROTEIN, MOUSE; ROCK2 PROTEIN, MOUSE;

ACTIN POLYMERIZATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA B16; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL MOTION; CONFOCAL MICROSCOPY; DRUG EFFECTS; GENETICS; HUMAN; MELANOMA, EXPERIMENTAL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULARIZATION; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; TUMOR BURDEN;

EID: 84942124062     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0523     Document Type: Article

References (52)

1. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Engl J Med 1995;333:1757-63.
2. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, et al. Vascular channel formation by humanmelanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-52.
3. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81.
4. Vartanian AA. Signaling pathways in tumor vasculogenic mimicry. Biochemistry (Mosc) 2012;779:1044-55.
5. Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 2004;25:1609-14.
6. Chung HJ, Mahalingam M. Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies. Expert Rev Anticancer Ther 2014;14:621-39.
7. Paulis YWJ, Soetekouw PM, Verheul HMW, Tjan-Heijnen VCG, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 2010;1806:18-28.
8. Van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Nat Cancer Inst 2004;96:1473-7.
9. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012;18:2726-32.
10. Larson AR, Lee CW, Lezcano C, Zhan Q, Huang J, Fischer AH, et al. Melanoma spheroid formation involves laminin-associated vasculogenic mimicry. Am J Pathol 2014;184:71-8.
11. Maes H, Van Eygen S, Krysko DV, Vandenabeele P, Nys K, Rillaerts K, et al. BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton. Cell Death Dis 2014;5:e1127.
12. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996;15:2208-16.
13. Murali A, Rajalingam K. Small Rho GTPases in the control of cell shape and mobility. Cell Mol Life Sci 2014;71:1703-21.
14. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009;28:65-76.
15. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796:91-8.
16. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006;5:2158-64.
17. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. Class IV semaphorins promote angiogenesis by stimulating rho-initiated pathways through Plexin-B. Cancer Res 2004;64:5212-24.
18. Basile JR, Gavard J, Gutkind JS. Plexin-B1 utilizes rhoa and rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem 2007;282:34888-95.
19. Connolly JO, Simpson N, Hewlett L, Hall A. Rac regulates endothelial morphogenesis and capillary assembly. Mol Biol Cell 2002;13:2474-85.
20. Hoang MV, Whelan MC, Senger DR. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A 2004;101:1874-9.
21. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50.
22. Liu AJ, Ling F, Wang D, Wang Q, Lü XD, Liu YL. Fasudil inhibits plateletderived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip1 via the ERK signal pathway. Chin Med J (Engl) 2011;124:3098-104.
23. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S) - (+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93:225-32.
24. Hyvelin JM, Howell K, Nichol A, Costello CM, Preston RJ, McLoughlin P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005;97:185-91.
25. Zhang Z, Ren JH, Li ZY, Nong L, Wu G. Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration. Onco Rep 2012;27:1561-6.
26. Yang X, Liu Y, Zong Z, Tian D. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother 2010;64:58-62.
27. Zhu F, Zhang Z, Wu G, Li Z, Zhang R, Ren J, et al. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol 2011;28:565-71.
28. Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007;6:1517-25.
29. Mettu PS, Deng PF, Misra UK, Gawdi G, Epstein DL, Rao PV. Role of lysophospholipid growth factors in the modulation of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2004;45:2263-71.
30. Hirakawa M, Oike M, Watanabe M, Karashima Y, Ito Y. Pivotal role of integrin alpha5beta1 in hypotonic stress-induced responses of human endothelium. FASEB J 2006;20:1992-9.
31. Jaganathan BG, Ruester B, Dressel L, Stein S, Grez M, Seifried E, et al. Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells 2007;25:1966-74.
32. Carr HS, Zuo Y, Oh W, Frost JA. Regulation of focal adhesion kinase activation breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1. Mol Cell Biol 2013;33:2773-86.
33. Mirshahi P, Rafii A, Vincent L, Berthaut A, Varin R, Kalantar G, et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 2009;23:1039-48.
34. Su F, Li B, Wang J, Xu X, Ren R, Li L, et al. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helixloophelix Id2 (inhibitor of DNA binding 2). Graefes Arch Clin Exp Ophthalmol 2009;247:411-9.
35. Zhang S, Guo H, Zhang D, Zhang W, Zhao X, Ren Z, et al. Microcirculation patterns in different stages of melanoma growth. Oncol Rep 2006;15:15-20.
36. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem 2009;284:27456-66.
37. Coleman ML, Olson MF. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 2002;9:493-504.
38. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol 2000;150:797-806
39. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLOS ONE 2008;3:e1652.
40. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33.
41. Sun D, Sun B, Liu T, Zhao X, Che N, GuQ, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma. J Cell Mol Med 2013;17:1038-47.
42. Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A, Lichinitser M. VEGFR1 and PKCa signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Melanoma Res 2011;21:91-8.
43. Fang M, Peng C, Liu S, Yuan J, Li Y. In Vitro invasive pattern of hepatocellular carcinoma cell line HCCLM9 based on three-dimensional cell culture and quantum dots molecular imaging. J Huazhong Univ Sci Technol Med Sci 2013;33:520-4.
44. Nakajima M, Hayashi K, Katayama K, Amano Y, Egi Y, Uehata M, et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 2003;459:113-20.
45. Deng L, Li G, Li R, Liu Q, He Q, Zhang J. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 2010;9:875-84.
46. Miyamoto C, Maehata Y, Ozawa S, Ikoma T, Kubota E, Izukuri K, et al. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK. J Pharmacol Sci 2012;120:241-9.
47. Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 2010;24:3186-95.
48. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011;7:657-71.
49. Nakabayashi H, Shimizu K. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogenactivated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci 2011;102:393-9.
50. Kitano K, Usui S, Ootsuji H, Takashima S, Kobayashi D, Murai H. Rhokinase activation in leukocytes plays a pivotal role in myocardial ischemia/reperfusion injury. PLoS One 2014;9:e92242.
51. Miyamoto C, Maehata Y, Ozawa S, Ikoma T, Kubota E, Izukuri K. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK. J Pharmacol Sci 2012;120:241-9.
52. Ogata S, Morishige K, Sawada K, Hashimoto K, Mabuchi S, Kawase C. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Int J Gynecol Cancer 2009;19:1473-80.